Julie Rathbun | Communications |
Jonathan Drachman | Chief Executive Officer |
Robert Ho | Chief Financial Officer |
Daniel-Adriano Silva | Head of Research |
Carl Walkey | Senior Vice President of Corporate Development |
Umut Ulge | Vice President of Clinical Development |
Tyler Van Buren | Piper Sandler |
Arlinda Lee | Canaccord Genuity |
Good morning and thank you for joining us today for the Neoleukin Therapeutics Conference Call. At this time, all participants are in a listen-only mode.
Following the conclusion of the prepared remarks, we will conduct a question-and-answer session and instructions will follow at that time.
As a reminder, today's conference call is being recorded. I would now like to turn the call over to Julie Rathbun, Communications for Neoleukin Therapeutics.